

Supplementary Table 1 Liver function in all visits

		Low-dose group	Medium-dose group	High-dose group	<i>P</i> value of viaration
ALB, g/L	Baseline	26.65±8.89	29.60±8.66	36.64±4.66	
	Day 29 th	31.23±6.15 ^a	30.11±10.48	41.06±4.41 ^c	0.2247
	Day 57 th	32.66±8.54 ^a	32.14±6.11	42.34±4.91 ^c	0.3303
	Day 85 th	31.79±7.80 ^a	34.02±7.11 ^b	41.89±3.75 ^c	0.6778
	Day 169 th	35.42±7.67	34.40±9.15	39.39±5.12	0.3681
ALT, U/L	Baseline	30.38±11.94	22.63±7.60	23.75±5.68	
	Day 29 th	33.88±19.53	23.94±9.80	24.50±4.24	0.7715
	Day 57 th	33.71±10.48	25.60±7.47	27.63±6.30	0.4889
	Day 85 th	35.71±14.47	29.33±9.42	31.14±6.72 ^c	0.6075
	Day 169 th	26.20±10.55	33.20±10.85	27.88±8.63	0.2608
AST, U/L	Baseline	41.63±16.66	39.00±18.17	26.75±4.89	
	Day 29 th	50.13±26.04	44.73±16.54	30.00±6.05	0.9869
	Day 57 th	50.86±21.40	49.00±12.17	31.13±6.56	0.6042
	Day 85 th	51.00±23.73	48.17±19.41	31.86±7.65	0.6407
	Day 169 th	37.20±8.79	49.60±19.81	38.00±25.99	0.2451

T-Bil, μmol/L	Baseline	25.45±9.39	39.15±26.74	24.31±8.00	
	Day 29 th	29.43±8.39	34.88±19.99 ^b	26.06±9.79	0.0108 ^d
	Day 57 th	28.71±9.52	49.87±30.88	25.40±11.78	0.5916
	Day 85 th	28.10±9.57	45.01±30.59	24.93±11.47	0.7924
	Day 169 th	37.58±19.76	36.51±31.85	37.74±50.70	0.4784
D-Bil, μmol/L	Baseline	6.58±2.93	9.60±8.57	5.76±2.06	
	Day 29 th	8.58±4.81	12.52±11.60	5.91±2.59	0.4460
	Day 57 th	7.51±3.01	16.71±15.09	6.54±4.37	0.1486
	Day 85 th	7.40±3.59	14.45±14.08	6.34±3.61	0.4538
	Day 169 th	17.42±16.54	13.73±17.99	20.60±43.91	0.3007
TC, mmol/L	Baseline	3.53±1.19	2.98±0.86	3.51±0.53	
	Day 29 th	3.94±1.36 ^a	3.51±0.76	3.92±0.67	0.8572
	Day 57 th	4.03±1.35	3.27±0.78	4.05±0.68 ^c	0.4726
	Day 85 th	4.31±0.97	3.92±0.66	3.98±0.69	0.1547
	Day 169 th	3.76±1.22	3.30±0.04	3.65±1.10	0.3210
CHE, U/L	Baseline	3502.25±2192.27	4678.38±2284.12	4970.63±1033.54	
	Day 29 th	4355.13±2198.20	4534.40±2016.49	5648.00±854.36 ^c	0.0664

Day 57 th	3854.50±2086.53	6196.00±4482.58	5981.14±835.44	0.7648
Day 85 th	3979.67±1459.44 ^a	3000.00±0.00	6023.80±926.19	0.2376
Day 169 th	3246.25±388.72	11115.00±0.00	5716.17±726.81	0.1449

^a*P* < 0.05 compared with baseline values in low-dose group ; ^b*P* < 0.05 compared with baseline values in medium-dose group ; ^c*P* < 0.05 compared with baseline values in high-dose group; ^d*P* < 0.05 compared among three group in the same visit.

Supplementary Table 2 Coagulation function in all visits

		Low-dose group	Medium-dose group	High-dose group	P value of viaration
PTTA, %	Baseline	64.13±9.37	63.88±16.12	69.63±10.38	
	Day 29 th	68.29±12.04	60.77±23.07	76.00±10.69 ^c	0.5401
	Day 57 th	71.79±11.43	67.80±26.91	79.04±15.50 ^c	0.6308
	Day 85 th	72.21±8.88	67.47±27.88	79.97±11.05 ^c	0.6753
	Day 169 th	59.83±13.99	73.15±27.45	82.20±8.92 ^c	0.0455 ^d
AT-III, mg/L	Baseline	53.14±18.42	65.25±18.31	64.63±14.36	
	Day 29 th	61.71±19.42 ^a	61.00±19.31	72.25±12.49 ^c	0.4837
	Day 57 th	52.13±17.61	-	78.43±13.77 ^c	0.2769
	Day 85 th	51.59±20.54	31.10±0.00	75.00±16.63	0.3075
	Day 169 th	72.00±7.07	85.00±0.00	77.17±16.02	0.5049

^a*P* < 0.05 compared with baseline values in low-dose group ; ^c*P* < 0.05 compared with baseline values in high-dose group; ^d*P* < 0.05 compared among three group in the same visit.

Supplementary Table 3 General condition in all visits

		Low-dose group	Medium-dose group	High-dose group	<i>P</i> value of viaration
weight, Kg	Baseline	64.34±5.32	71.89±9.30	72.06±9.83	
	Day 29 th	62.76±5.69	72.71±15.06	73.11±9.69	0.0956
	Day 57 th	62.49±5.93	75.33±10.50	74.15±8.65	0.0686
	Day 85 th	63.90±5.60	70.25±12.82	71.90±9.63	0.7195
	Day 169 th	59.88±6.01	68.95±12.73	71.50±9.91	0.7668
Child-Pugh	Baseline	8.25±0.71	7.88±2.47	6.13±1.25	
	Day 29 th	7.13±1.46	7.50±2.81	5.50±0.76	0.4995
	Day 57 th	6.86±1.21 ^a	8.00±4.24	5.75±1.39	0.2323
	Day 85 th	7.00±1.29	8.00±2.97	5.43±0.53	0.4074
	Day 169 th	7.40±1.82	6.80±2.68	6.00±1.69	0.8314
MELD	Baseline	7.25±2.49	9.25±5.90	7.63±2.50	
	Day 29 th	8.88±1.81	8.29±5.31	7.38±1.85	0.0801
	Day 57 th	8.43±2.44	10.00±8.49	6.38±2.33	0.1415
	Day 85 th	8.43±2.64	9.33±6.31	6.57±1.99	0.3997
	Day 169 th	8.00±2.65	7.40±6.54	6.75±2.49	0.9443

SF36 scale	Day 85 th	95.5±14.85	96.2±17.63	98.8±7.49	0.9286
	Day 169 th	109.5±4.95	94.4±5.81	98.4±7.61	0.0650

^a*P* < 0.05 compared with baseline values in low-dose group.

Supplementary Table 4 Ascites in each visit

Visit time	Group	N (Missing)	-/-	-/+	+/-	+/+
Day 29	Low-dose	8 (0)	0	1	5	2
	Medium-dose	6 (2)	2	1	2	1
	High-dose	8 (0)	4	1	3	0
Day 57	Low-dose	7 (1)	1	0	3	3
	Medium-dose	2 (6)	1	0	1	0
	High-dose	8 (0)	4	1	3	0
Day 85	Low-dose	7 (1)	1	0	2	4
	Medium-dose	5 (3)	1	0	2	2
	High-dose	7 (1)	4	0	2	1
Day 169	Low-dose	4 (4)	0	0	1	3
	Medium-dose	5 (3)	2	0	3	0
	High-dose	8 (0)	3	2	2	1

Annotation: “-” means negative, “+” means positive. Symbols before “/” means condition of baseline. Symbols after “/” means condition of this visit.

Supplementary Table 5 Edema of legs in each visit

Visit time	Group	N(Missing)	-/-	-/+	+/-	+/+
Day 29	Low-dose	7(1)	1	0	2	4
	Medium-dose	6(2)	3	1	2	0
	High-dose	8(0)	7	0	1	0
Day 57	Low-dose	7(1)	1	0	5	1
	Medium-dose	5(3)	3	0	2	0
	High-dose	7(1)	6	0	1	0
Day 85	Low-dose	7(1)	1	0	5	1
	Medium-dose	6(2)	4	0	2	0
	High-dose	7(1)	6	0	1	0
Day 169	Low-dose	3(5)	1	0	1	1
	Medium-dose	5(3)	4	0	1	0
	High-dose	8(0)	6	1	1	0

Annotation: “-” means negative, “+” means positive. Symbols before “/” means condition of baseline. Symbols after “/” means condition of this visit.

Supplementary Table 6 Haematemesis in each visit

Visit time	Group	N (Missing)	-/-	-/+	+/-	+/+
Day 29	Low-dose	7(1)	6	1	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	8(0)	8	0	0	0
Day 57	Low-dose	7(1)	7	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	7(1)	8	0	0	0
Day 85	Low-dose	7(1)	7	0	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	7(1)	7	0	0	0
Day 169	Low-dose	3(5)	3	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	8(0)	8	0	0	0

Annotation: “-” means negative, “+” means positive. Symbols before “/” means condition of baseline. Symbols after “/” means condition of this visit.

Supplementary Table 7 Jaundice in each visit

Visit time	Group	N(Missing)	-/-	-/+	+/-	+/+
Day 29	Low-dose	7(1)	6	1	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	8(0)	7	0	1	0
Day 57	Low-dose	7(1)	7	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	7(1)	7	0	1	0
Day 85	Low-dose	7(1)	7	0	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	7(1)	6	0	1	0
Day 169	Low-dose	3(5)	3	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	8(0)	7	0	1	0

Annotation: “-” means negative, “+” means positive. Symbols before “/” means condition of baseline. Symbols after “/” means condition of this visit.

Supplementary Table 8 Poor appetite in each visit

Visit time	Group	N (Missing)	-/-	-/+	+/-	+/+
Day 29	Low-dose	7(1)	6	1	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	8(0)	8	0	0	0
Day 57	Low-dose	7(1)	7	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	7(1)	8	0	0	0
Day 85	Low-dose	7(1)	7	0	0	0
	Medium-dose	6(2)	6	0	0	0
	High-dose	7(1)	7	0	0	0
Day 169	Low-dose	3(5)	3	0	0	0
	Medium-dose	5(3)	5	0	0	0
	High-dose	8(0)	8	0	0	0

Annotation: “-” means negative, “+” means positive. Symbols before “/” means condition of baseline. Symbols after “/” means condition of this visit.

Supplementary Table 9 Immune function in visit of all visits

		Low-dose group	Medium-dose group	High-dose group	P value of viaration
CD4+ T cell, /μL	Baseline	309.25±119.35	403.29±261.76	428.88±197.73	
	Day 29 th	296.14±111.72	272.50±263.75	443.88±258.63	0.3981
	Day 57 th	280.71±98.90	-	545.14±290.77	0.1797
	Day 85 th	339.00±171.65	327.00±0.00	542.80±239.18	0.9630
	Day 169 th	230.00±206.48	344.00±22.63	473.83±213.52	0.3815
CD8+ T cell, /μL	Baseline	204.75±123.31	168.74±109.99	217.63±103.32	
	Day 29 th	204.75±123.31	168.74±109.99	217.63±103.32	0.6978
	Day 57 th	266.86±199.53	-	298.00±197.26	0.1417
	Day 85 th	242.14±209.52	235.00±0.00	245.80±188.32	0.9033
	Day 169 th	275.50±310.42	301.50±7.78	449.50±573.23	0.2904
Th1 cell, %	Baseline	12.36±10.63	21.73±8.60	23.85±14.64	
	Day 29 th	17.66±14.80	24.90±1.98	16.16±18.79	0.6116
	Day 57 th	20.15±12.39	-	17.67±13.09	0.1417
	Day 85 th	8.06±7.72	28.91±0.00	29.48±21.44	0.8040
	Day 169 th	31.55±12.37	14.50±18.66	28.62±17.23	0.2335

Th2 cell, %	Baseline	1.33±0.75	5.67±7.55	1.54±1.16	
	Day 29 th	1.40±0.57	0.70±0.14	2.58±2.16	0.3251
	Day 57 th	1.75±1.27	-	1.99±1.11	>0.9999
	Day 85 th	0.78±0.97	20.76±0.00	0.98±0.33	0.3886
	Day 169 th	1.00±0.71	12.18±14.96	1.17±0.54	0.5589
NK cell, /μL	Baseline	255.88±217.47	236.86±142.79	198.75±175.22	
	Day 29 th	384.57±404.65 ^a	216.00±209.30	291.00±265.33	0.3289
	Day 57 th	365.00±334.65	-	461.38±461.40 ^c	0.4875
	Day 85 th	327.00±325.51	399.00±0.00	418.00±381.27	0.4658
	Day 169 th	638.50±854.89	870.00±0.00	564.83±380.86	0.3012
NK-T cell, %	Baseline	7.26±6.81	8.90±10.22	1.88±1.35	
	Day 29 th	5.86±6.49	8.85±4.31	2.89±2.67	0.5752
	Day 57 th	6.45±5.63	-	7.39±7.32	0.1985
	Day 85 th	5.60±3.73	-	2.12±0.91	0.2948
	Day 169 th	1.35±0.64	8.50±0.00	3.82±2.70	0.0608
IL-1, pg/mL	Baseline	3.64±1.61	2.45±0.91	3.07±2.95	
	Day 29 th	2.79±0.48	2.49±0.82	2.75±2.31	0.9031

IL-4, pg/mL	Day 57 th	2.96±1.07	-	2.73±2.93	0.5677
	Day 85 th	10.74±16.36	-	1.80±1.29	0.0651
	Day 169 th	5.38±5.70	1.47±0.00	1.51±0.77	0.3792
	Baseline	3.25±0.99	2.32±1.02	2.79±1.35	
	Day 29 th	2.83±1.23	4.35±3.80	3.00±2.30	0.5992
	Day 57 th	2.46±0.55	10.00±0.00	2.98±2.87	0.2366
	Day 85 th	6.88±10.24	1.39±0.00	3.69±2.26	0.5115
	Day 169 th	18.44±27.54	5.79±5.96	2.67±2.06	0.4613
IL-6, pg/mL	Baseline	19.26±37.51	6.19±2.40	5.62±2.90	
	Day 29 th	13.89±23.11	4.92±3.39	4.39±1.70	0.1609
	Day 57 th	11.22±12.52	2.60±0.00	4.03±3.06	0.5070
	Day 85 th	15.78±20.63	17.28±0.00	2.80±2.49	0.1614
	Day 169 th	23.16±32.08	6.86±4.96	3.35±1.82	0.7752
IL-8, pg/mL	Baseline	12.79±5.85	9.47±4.92	9.02±5.83	
	Day 29 th	8.23±3.64 ^a	3.84±1.66	5.57±4.04 ^c	0.4977
	Day 57 th	8.37±4.07	-	3.58±3.97 ^c	>0.9999
	Day 85 th	14.63±8.10	-	7.97±15.62	0.3367

IL-12, pg/mL	Day 169 th	28.13±26.84	6.22±0.00	2.69±1.67 ^c	0.0491 ^d
	Baseline	2.89±2.97	2.24±1.72	0.94±0.64	
	Day 29 th	2.64±1.76	1.42±0.73	1.30±0.63	0.6270
	Day 57 th	1.85±1.28	-	1.01±1.26	>0.9999
	Day 85 th	2.50±1.33	-	1.06±1.32	0.7488
IL-15, pg/mL	Day 169 th	4.35±6.20	0.38±0.00	1.14±1.32	0.2342
	Baseline	555.78±616.43	57.41±91.99	20.61±18.01	
	Day 29 th	258.08±250.57	15.60±0.00	23.21±15.37	0.0559
	Day 57 th	477.02±669.56	-	22.66±15.52	0.3146
	Day 85 th	275.32±229.96	-	20.48±15.43	0.8551
IL-17α, pg/mL	Day 169 th	253.70±194.43	15.60±0.00	19.52±17.72	0.0647
	Baseline	3.82±4.33	0.06±0.16	0.00±0.00	
	Day 29 th	0.72±1.20	0.67±1.15	0.22±0.61	0.1635
	Day 57 th	0.83±1.48	-	0.00±0.00	0.0425 ^d
	Day 85 th	11.02±15.25	-	0.25±0.61	0.6691
	Day 169 th	10.24±17.74	0.00±0.00	0.24±0.64	0.6331

^a $P < 0.05$ compared with baseline values in low-dose group ; ^c $P < 0.05$ compared with baseline values in high-dose group; ^d $P < 0.05$ compared among three group in the same visit.